Customized quality controls for analytical assays

US9909959B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9909959-B2
Application numberUS-201615296901-A
CountryUS
Kind codeB2
Filing dateOct 18, 2016
Priority dateSep 20, 2011
Publication dateMar 6, 2018
Grant dateMar 6, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Solid beads each containing a selected quantity of analyte are combined and a liquid base matrix that contains attributes of a biological fluid that is to be assayed, together constitute a kit from which a laboratory technician can, at the point of use, prepare a liquid control for a particular analyte, and preferably a series of such controls at different levels of the same analyte customized for a particular assay.

First claim

Opening claim text (preview).

What is claimed is: 1. A method for determining linearity of an assay response, said method comprising: dissolving one or more solid water-soluble beads in three or more aliquots of an aqueous liquid matrix to prepare three or more liquid solutions each having a different analyte level, wherein the water-soluble beads comprise at least one analyte, a bulking agent, a salt, and a buffer, and said aqueous liquid matrix comprising a salt and a buffer at a pH of from about 4.0 to about 9.0, performing the assay with the three or more liquid solutions to generate an assay response for the analyte in each of the three or more liquid solutions; and determining whether assay responses are linear within a range of analyte concentrations spanned by three or more liquid solutions, thereby determining linearity of an assay response. 2. The method of claim 1 , wherein the water-soluble beads are prepared by lyophilization of an aqueous solution ranging in volume from about 5 μL to about 1,000 μL. 3. The method of claim 1 , wherein dissolving comprises dissolving a plurality of quantities of one or more solid water soluble beads in separate aliquots and the aliquots have equal volumes of the aqueous liquid matrix. 4. The method of claim 1 , wherein dissolving comprises dissolving the same quantity of beads in separate aliquots, and the aliquots have different volumes of the aqueous liquid matrix. 5. The method of claim 1 , wherein the range of analyte concentrations includes concentrations above, below or equal to a known medical decision point concentration for the analyte. 6. The method of claim 1 , wherein at least one of said solid water-soluble beads consists essentially of at least one said analyte, said bulking agent, said salt, and a buffer. 7. The method of claim 1 , wherein said aqueous liquid matrix comprises human or animal source materials from which endogenous species that interfere with the detection of said analytes have been removed. 8. The method of claim 7 , wherein said human or animal source materials comprise a human biological fluid. 9. The method of claim 1 , wherein said aqueous liquid matrix further comprises an albumin. 10. The method of claim 9 , wherein said albumin is selected from the group consisting of human serum albumin and bovine serum albumin. 11. The method of claim 1 , wherein said aqueous liquid matrix further comprises a stabilizer selected from the group consisting of a protease inhibitor, a cryoprotectant, a reducing agent, a chelating agent, a crosslinking agent, and a surfactant. 12. The method of claim 1 , wherein said aqueous liquid matrix further comprises an antimicrobial agent selected from the group consisting of sodium azide, ciprofloxacin, chloramphenicol, gentamicin, amikacin, tobramycin, and amphotericin B. 13. The method of claim 1 , wherein said aqueous liquid matrix has a pH of from about 6.2 to about 8.5. 14. The method of claim 1 , wherein said aqueous liquid matrix has an osmolarity of from about 50 to about 1,000 mOsm/kg. 15. The method of claim 1 , wherein each said water-soluble bead is substantially spherical with a diameter of from about 3 mm to about 10 mm.

Assignees

Inventors

Classifications

  • G01N33/96Primary

    involving blood or serum control standard · CPC title

  • Serum albumin, e.g. HSA · CPC title

  • using penetration of dyes, e.g. fluorescent ink · CPC title

  • involving dehydrogenase · CPC title

  • Reference solutions for assays of biological material · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9909959B2 cover?
Solid beads each containing a selected quantity of analyte are combined and a liquid base matrix that contains attributes of a biological fluid that is to be assayed, together constitute a kit from which a laboratory technician can, at the point of use, prepare a liquid control for a particular analyte, and preferably a series of such controls at different levels of the same analyte customized …
Who is the assignee on this patent?
Bio Rad Laboratories
What technology area does this patent fall under?
Primary CPC classification G01N33/96. Mapped technology areas include Physics.
When was this patent published?
Publication date Tue Mar 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).